Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:01:11 2024-05-17 pm EDT			5-day change	1st Jan Change
28.64 ^USD	-0.97%		+1.63%	-0.52%

May. 17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE
May. 17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 01, 2024 at 08:11 am EDT

Pfizer Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 14,879 million compared to USD 18,486 million a year ago. Net income was USD 3,115 million compared to USD 5,543 million a year ago.

Basic earnings per share from continuing operations was USD 0.55 compared to USD 0.98 a year ago. Diluted earnings per share from continuing operations was USD 0.55 compared to USD 0.97 a year ago. Basic earnings per share was USD 0.55 compared to USD 0.98 a year ago.

Diluted earnings per share was USD 0.55 compared to USD 0.97 a year ago.

Latest news about Pfizer, Inc.

Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	May. 17	RE
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	May. 17	MT
Sector Update: Health Care	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports	May. 17	RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner	May. 17	RE
GSK sells remaining Haleon stake for GBP1.25 billion	May. 17	AN
GSK raises $1.5 bln from sale of remaining Haleon stake	May. 17	RE
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update	May. 16	DJ
Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon...	May. 16
Sector Update: Health Care Stocks Steady Premarket Thursday	May. 16	MT
Sector Update: Health Care	May. 16	MT
Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	May. 16	MT
Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	May. 16	MT
Pfizer Offers to Settle Zantac Claims for Up to $250 Million	May. 16	MT
Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales	May. 16	MT
Pfizer offers up to $250 million to settle thousands of Zantac cancer lawsuits, FT reports	May. 16	RE
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update	May. 13	DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update	May. 13	DJ
Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France	May. 13	MT

Chart Pfizer, Inc.

Duration

Period

More charts

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - Abstract No: LBA8503

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.92 USD

Average target price

31.94 USD

Spread / Average Target

+10.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-0.52%	164B
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

EPS Revisions